Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 99 articles:
HTML format
Text format



Single Articles


    May 2017
  1. ZUCMAN D, Farfour E, Mazaux L, Hillaire S, et al
    How to face the outbreak of viral hepatitis A in men-who-have-sex-with-men in France without vaccines?
    Clin Infect Dis. 2017 May 16. doi: 10.1093.
    PubMed     Text format    


  2. BOSCHI C, Colson P, Tissot-Dupont H, Bernit E, et al
    Hepatitis C virus relapse 78 weeks after completion of successful direct acting therapy.
    Clin Infect Dis. 2017 May 16. doi: 10.1093.
    PubMed     Text format    


  3. MOON J, Hyland RH, Zhang F, Brainard DM, et al
    Efficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease.
    Clin Infect Dis. 2017 May 13. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2017
  4. ROSENBERG ES, Hall EW, Sullivan PS, Sanchez TH, et al
    Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010.
    Clin Infect Dis. 2017 Apr 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. OZARAS R, Balkan II, Yemisen M, Mete B, et al
    Reactivation of Hepatitis B Virus Following Treatment of Hepatitis C Virus Infection in Coinfected Patients.
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format    


  6. BUTT AA, Yan P, Chew KW, Currier J, et al
    Risk of Acute Myocardial Infarction Among HCV+ and HCV- Men at Various Lipid Levels: Results from ERCHIVES.
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. TIEN PC
    HCV-associated Alterations in Lipid and Lipoprotein levels: Helpful or Harmful to the Heart?
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format    


  8. CANARY L, Hariri S, Campbell C, Young R, et al
    Geographic disparities in access to syringe services programs among young people with hepatitis C virus infection in the U.S.
    Clin Infect Dis. 2017 Apr 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. MORRIS MD, Shiboski S, Bruneau J, Hahn JA, et al
    Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration.
    Clin Infect Dis. 2017;64:860-869.
    PubMed     Text format     Abstract available


  10. NOSKA AJ, Belperio PS, Loomis TP, O'Toole TP, et al
    Prevalence of HIV, HCV and HBV among Homeless and Non-homeless United States Veterans.
    Clin Infect Dis. 2017 Apr 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  11. WYLES D, Brau N, Kottilil S, Daar ES, et al
    Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study.
    Clin Infect Dis. 2017 Mar 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. BUTT AA, Ren Y, Lo Re V 3rd, Taddei T, et al
    Comparing Child-Pugh, MELD and FIB-4 to Predict Clinical Outcomes in HCV-Infected Persons: Results from ERCHIVES.
    Clin Infect Dis. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. CEPEDA JA, Thomas DL, Astemborski J, Sulkowski MS, et al
    Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study.
    Clin Infect Dis. 2017 Mar 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. HEZODE C, Fourati S, Chevaliez S, Scoazec G, et al
    Sofosbuvir-Daclatasvir-Simeprevir plus Ribavirin in Direct-Acting Antiviral-Experienced Hepatitis C Patients.
    Clin Infect Dis. 2017 Mar 10. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  15. NAGGIE S, Marks KM, Hughes M, Fierer DS, et al
    Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
    Clin Infect Dis. 2017 Feb 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. ANDERSON ES, Galbraith JW, Deering LJ, Pfeil SK, et al
    Continuum of Care for HCV Among Patients Diagnosed in the Emergency Department Setting.
    Clin Infect Dis. 2017 Feb 16. doi: 10.1093.
    PubMed     Text format    


  17. LO RE V
    Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.
    Clin Infect Dis. 2017;64:498-500.
    PubMed     Text format    


  18. KOVARI H, Rauch A, Kouyos R, Rougemont M, et al
    Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study.
    Clin Infect Dis. 2017;64:490-497.
    PubMed     Text format    


  19. BLOCK TM, Locarnini S, McMahon BJ, Rehermann B, et al
    Use of current and new endpoints in the evaluation of experimental hepatitis B therapeutics.
    Clin Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  20. YOUNG J, Rossi C, Gill J, Walmsley S, et al
    Risk factors for hepatitis C virus reinfection after sustained virologic response in patients co-infected with HIV.
    Clin Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  21. BHATTACHARYA D, Belperio PS, Shahoumian TA, Loomis TP, et al
    Effectiveness of All-Oral Antiviral Regimens in 996 Genotype 1 HIV/HCV Coinfected Patients Treated in Routine Practice.
    Clin Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


  22. BURTON MJ, Naggie S
    Real World Effectiveness of DAA Therapies in HIV/HCV Co-Infection: 996 Veterans Can't Be Wrong.
    Clin Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


  23. BEGUELIN C, Friolet N, Moradpour D, Sahli R, et al
    Impact of tenofovir on hepatitis delta virus replication in the Swiss HIV Cohort Study.
    Clin Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


  24. ANDREONI M, Teti E, Antinori A, Milazzoi L, et al
    Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program.
    Clin Infect Dis. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    


  25. VEENHUIS RT, Astemborski J, Chattergoon MA, Greenwood P, et al
    Systemic Elevation of Proinflammatory Interleukin-18 in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Coinfection Versus HIV or HCV Monoinfection.
    Clin Infect Dis. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    


    January 2017
  26. RIVERO-JUAREZ A, Frias M, Lopez-Lopez P, Risalde ML, et al
    Hepatitis E virus infection in anti-HEV IgG-carryinfing patients after successful HCV treatment: reactivation or reinfection?
    Clin Infect Dis. 2017 Jan 11. pii: cix004. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2016
  27. MASSIMO A, Teti E, Antinori A, Milazzoi L, et al
    Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program.
    Clin Infect Dis. 2016 Dec 22. pii: ciw846. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. LO RE V 3RD
    Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  29. KOVARI H, Rauch A, Kouyos R, Rougemont M, et al
    Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  30. FORD MM, Johnson N, Desai P, Rude E, et al
    From Care to Cure: Demonstrating a Model of Clinical Patient Navigation for Hepatitis C Care and Treatment in High-Need Patients.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  31. VEENHUIS RT, Astemborski J, Chattergoon MA, Greenwood P, et al
    Systemic Elevation of Proinflammatory Interleukin 18 in HIV/HCV Coinfection versus HIV or HCV Monoinfection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    November 2016
  32. LIEVELD FI, Arends JE, Amelung L, Dijk E, et al
    Overcoming Outpatient Loss to Follow-up as a Barrier to Efficiently Instituting Hepatitis B Liver-related Care.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  33. FOSTER AL, Gaisa MM, Hijdra RM, Turner SS, et al
    Shedding of Hepatitis C Virus Into the Rectum of HIV-infected Men Who Have Sex With Men.
    Clin Infect Dis. 2016 Nov 9. pii: ciw740. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. BAROCAS JA, Linas BP
    Decision Science at Work: The Case of Hepatitis C Virus Postexposure Prophylaxis.
    Clin Infect Dis. 2016.
    PubMed     Text format    


    October 2016
  35. SARRAZIN C, Isakov V, Svarovskaia E, Hedskog C, et al
    Late relapse versus HCV reinfection in patients with sustained virologic response after sofosbuvir-based therapies.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    September 2016
  36. NAGGIE S, Holland D, Sulkowski MS, Thomas DL, et al
    HCV post-exposure prophylaxis in the healthcare worker: Why DAAs don't change a thing.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  37. MOORE MS, Ivanina E, Bornschlegel K, Qiao B, et al
    Hepatocellular Carcinoma and Viral Hepatitis in New York City.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  38. GREBELY J, Dore GJ, Zeuzem S, Aspinall RJ, et al
    Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of Phase 3 ASTRAL trials.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  39. GREBELY J, Mauss S, Brown A, Bronowicki JP, et al
    Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of Phase 3 ION trials.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  40. INGILIZ P, Christensen S, Kimhofer T, Hueppe D, et al
    Sofosbuvir and Ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus infection in HCV-mono-infected and HIV-HCV co-infected individuals - Results from the German hepatitis C cohort (GECCO-01).
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  41. KLEVENS RM, Canary L, Huang X, Denniston MM, et al
    The Burden of Hepatitis C Infection-Related Liver Fibrosis in the United States.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  42. KLEIN MB, Althoff KN, Jing Y, Lau B, et al
    Risk of endstage liver disease in HIV-viral hepatitis co-infected persons in North America from the early to modern antiretroviral therapy eras.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  43. ABRAVANEL F, Metivier S, Chauveau M, Peron JM, et al
    Transmission of HCV NS5A inhibitor-resistant variants among HIV-infected men who have sex with men.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  44. KAMSTRA R, Azoulay L, Steele R, Klein MB, et al
    Hospitalizations in immigrants and non-immigrants diagnosed with chronic hepatitis C infection in Quebec.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  45. SPRADLING PR, Xing J, Rupp LB, Moorman AC, et al
    Infrequent clinical assessment of chronic hepatitis B patients in United States general healthcare settings.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  46. MCMAHON BJ
    Sliding Down the Cascade of Care for Chronic Hepatitis B Virus Infection.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  47. SULKOWSKI MS, Chuang WL, Kao JH, Yang JC, et al
    No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    July 2016
  48. YOUNOSSI ZM, Stepanova M, Sulkowski M, Foster GR, et al
    Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and 3 Clinical Trials.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available



  49. Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  50. WYLES DL, Sulkowski MS, Dieterich D
    Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.
    Clin Infect Dis. 2016;63 Suppl 1:S3-S11.
    PubMed     Text format     Abstract available


  51. MACBRAYNE CE, Kiser JJ
    Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.
    Clin Infect Dis. 2016;63 Suppl 1:S12-23.
    PubMed     Text format     Abstract available


  52. ROWAN SE, Rogers M, Bayer J, Smith L, et al
    Treatment of HCV in HIV coinfected individuals in real world clinical settings: results from two large HIV care clinics.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  53. AL-KINDI SG, Zidar DA, McComsey GA, Longenecker CT, et al
    Gender differences in statin prescription rate among patients living with HIV and HCV.
    Clin Infect Dis. 2016.
    PubMed     Text format    


    June 2016
  54. FEDELI U, Schievano E
    Mortality waves related to Hepatitis C virus infection: multiple causes of death data from the US and Northern Italy compared.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  55. FELD JJ, Maan R, Zeuzem S, Kuo A, et al
    Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-TARGET study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  56. SOGNI P, Gilbert C, Lacombe K, Piroth L, et al
    All-oral DAA regimens in HIV-HCV coinfected cirrhotic patients are efficient and safe. Real-life results from the prospective ANRS CO13 - HEPAVIH cohort.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  57. GJAERDE LI, Shepherd L, Jablonowska E, Lazzarin A, et al
    Trends in incidences and risk factors for hepatocellular carcinoma and other liver events in HIV and hepatitis C virus co-infected individuals from 2001 to 2014: a multi-cohort study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  58. HEDENSTIERNA M, Nangarhari A, Weiland O, Aleman S, et al
    Diabetes and cirrhosis are risk factors for hepatocellular carcinoma after successful treatment of chronic hepatitis C.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  59. WILSON EM, Tang L, Kottilil S
    Eradication Strategies for Chronic Hepatitis B Infection.
    Clin Infect Dis. 2016;62 Suppl 4:S318-25.
    PubMed     Text format     Abstract available


  60. TRAN TT
    Hepatitis B in Pregnancy.
    Clin Infect Dis. 2016;62 Suppl 4:S314-7.
    PubMed     Text format     Abstract available


  61. GONZALEZ SA, Perrillo RP
    Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy.
    Clin Infect Dis. 2016;62 Suppl 4:S306-13.
    PubMed     Text format     Abstract available


  62. WONG GL, Wong VW, Chan HL
    Virus and Host Testing to Manage Chronic Hepatitis B.
    Clin Infect Dis. 2016;62 Suppl 4:S298-305.
    PubMed     Text format     Abstract available


  63. SHANKAR H, Blanas D, Bichoupan K, Ndiaye D, et al
    A Novel Collaborative Community-Based Hepatitis B Screening and Linkage to Care Program for African Immigrants.
    Clin Infect Dis. 2016;62 Suppl 4:S289-97.
    PubMed     Text format     Abstract available


  64. DANDRI M, Petersen J
    Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.
    Clin Infect Dis. 2016;62 Suppl 4:S281-8.
    PubMed     Text format     Abstract available


    May 2016
  65. COOPER C, Naggie S, Saag M, Yang JC, et al
    Successful Retreatment of HCV in Patients Coinfected with HIV Who Failed 12 Weeks of Ledipasvir/Sofosbuvir.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  66. KELLY EM, Dodge JL, Sarkar M, French AL, et al
    Marijuana Use is not Associated with Progression to Advanced Liver Fibrosis in HIV/HCV Coinfected Women.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  67. SOLLIMA S, D'Avolio A, Cattaneo D, Micheli V, et al
    Darunavir-based antiretroviral therapy may affect the efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir in HCV/HIV-1 coinfected patients.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  68. CLEMENT ME, Park LP, Navar AM, Okeke NL, et al
    Statin Utilization and Recommendations Among HIV and HCV-Infected Veterans: A Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    April 2016
  69. KANWAL F, Kramer JR, El-Serag HB, Frayne S, et al
    Race and gender differences in the use of direct acting antiviral agents for HCV.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  70. NICOLAS D, Esteve A, Cuadros A, Campbell CN, et al
    Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  71. RAMSAY I, Gorton RL, Patel M, Workman S, et al
    Transmission of Hepatitis B core Antibody and Galactomannan Enzyme Immunoassay positivity via immunoglobulin products: a comprehensive analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  72. SHAFRAN SD
    Reply to Menard et al.
    Clin Infect Dis. 2016;62:949-50.
    PubMed     Text format    


    March 2016
  73. LUETKEMEYER AF, McDonald C, Ramgopal M, Noviello S, et al
    12 Weeks of Daclatasvir in Combination with Sofosbuvir for HIV-HCV Coinfection (ALLY-2 study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  74. RIVERO-JUAREZ A, Frias M, Rodriguez-Cano D, Cuenca-Lopez F, et al
    Isolation of Hepatitis E virus from breast milk during acute infection.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  75. TOSTI ME, Alfonsi V, Lacorte E, Mele A, et al
    Acute hepatitis B after the implementation of universal vaccination in Italy: results from a 22-years surveillance (1993-2014).
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  76. LY KN, Hughes EM, Jiles RB, Holmberg SD, et al
    Rising Mortality Associated with Hepatitis C Virus in the United States, 2003-2013.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  77. DEL BELLO D, Cha A, Sorbera M, Bichoupan K, et al
    Real-world Sustained Virologic Response Rates of Sofosbuvir-containing Regimens in Patients Coinfected with Hepatitis C and HIV.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    February 2016
  78. HSIEH YH, Rothman RE, Laeyendecker OB, Kelen GD, et al
    Evaluation of The CDC Recommendations for HCV Testing in an Urban Emergency Department.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  79. LYONS MS, Kunnathur VA, Rouster SD, Hart KW, et al
    Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  80. MARTIN NK, Thornton A, Hickman M, Sabin C, et al
    Can HCV direct-acting antiviral treatment as prevention reverse the HCV epidemic amongst men who have sex with men in the UK - epidemiological and modelling insights.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  81. JONAS MC, Rodriguez CV, Redd J, Sloane DA, et al
    Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  82. HARRINGTON PR, Fleischer R, Connelly SM, Lewis LL, et al
    Reply to Merli et al.
    Clin Infect Dis. 2016;62:528-9.
    PubMed     Text format    


  83. VERMEHREN J, Maasoumy B, Maan R, Cloherty G, et al
    Applicability of HCV RNA viral load thresholds for 8-week treatments in patients with chronic hepatitis C genotype 1 infection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    January 2016
  84. KUNCIO DE, Newbern EC, Johnson CC, Viner KM, et al
    Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C-Positive Women.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  85. SIMMONS B, Saleem J, Hill A, Riley RD, et al
    Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  86. SAEED S, Strumpf EC, Walmsley S, Rollet-Kurhajec K, et al
    How generalizable are the results from trials of Direct Antiviral Agents to people coinfected with HIV/Hepatitis C virus in the real world?
    Clin Infect Dis. 2016 Jan 6. pii: civ1222.
    PubMed     Text format     Abstract available


  87. MARTINELLO M, Dore GJ
    HCV direct-acting antivirals in the "real world": Efficacy comparable to clinical trials.
    Clin Infect Dis. 2016 Jan 6. pii: civ1227.
    PubMed     Text format    


  88. MENARD A, Colson P, Catherine D, Isabelle R, et al
    First real life evidence of new direct-acting antivirals (DAA) in co-infected HIV HCV patients: better than ever.
    Clin Infect Dis. 2016 Jan 5. pii: civ1215.
    PubMed     Text format    


  89. KHATRI A, Dutta S, Wang H, Podsadecki T, et al
    Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
    Clin Infect Dis. 2016 Jan 5. pii: civ1213.
    PubMed     Text format     Abstract available


  90. STOCKDALE AJ, Geretti AM
    Reply to Boyd and Lacombe.
    Clin Infect Dis. 2016;62:130-1.
    PubMed     Text format    


  91. KESHTKAR-JAHROMI M, Rassaei N, Bruno MA, Maneval ML, et al
    Photo Quiz. A 59-Year-Old Man With Multiple Liver Lesions, Rash, and Uveitis.
    Clin Infect Dis. 2016;62:82-3.
    PubMed     Text format    


    November 2015
  92. DURHAM DP, Skrip LA, Bruce RD, Vilarinho S, et al
    The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  93. DONNELLY JP, Franco R, Wang HE, Galbraith JW, et al
    Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  94. HONER ZU SIEDERDISSEN C, Maasoumy B, Marra F, Deterding K, et al
    Drug-drug interactions with novel all oral interferon free antiviral agents in a large real-world cohort.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    September 2015
  95. BOYD A, Lacombe K
    More long-term assessment of transient elastography is needed for HIV-HBV co-infected patients undergoing treatment with tenofovir.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  96. BALAGOPAL A, Thomas DL
    Editorial Commentary: Who is "Special" Now?
    Clin Infect Dis. 2015;61:826-8.
    PubMed     Text format    


    August 2015
  97. SIDHARTHAN S, Kohli A, Kottilil S
    Reply to Harrington et al.
    Clin Infect Dis. 2015;61:667-8.
    PubMed     Text format    


    July 2015
  98. STARK JE
    Potential for a Significant Interaction Between Clopidogrel and Dasabuvir.
    Clin Infect Dis. 2015;61:134-5.
    PubMed     Text format    


    November 2014
  99. ABRAHAM AG, Althoff KN, Jing Y, Estrella MM, et al
    End Stage Renal Disease Among HIV-Infected Adults in North America.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: